Type 2 diabetes and obesity could be treated by new, less invasive procedure

surgery
Credit: CC0 Public Domain

New research from King's College London published in EBioMedicine, has found that a newly tested medical device, called Sleeveballoon, mimics the effects of traditional bariatric surgery in rodents and produces impressive results on body weight, fatty liver and diabetes control.

Sleeveballoon is a device that combines a balloon with a connected sleeve, which covers the initial parts of the small intestine. It is inserted into the stomach and bowel during minimally invasive surgery under general anaesthetic.

In this study, researchers compared the effects of the Sleeveballoon and traditional bariatric surgery on 30 rodents fed with a , achieving very similar results. Results were also compared to sham-operated rats, with the new device reducing by 60% and resulting in a 57% reduction in fat mass. The effect on diabetes was similarly impressive with blood glucose levels dropping by 65%.

"Gastric bypass surgery is a highly effective treatment of obesity and type 2 diabetes. However, very few eligible patients, only around 1%, are offered surgery and some also prefer less invasive approaches," said lead author Professor Geltrude Mingrone from King's College London.

"We found that the metabolic effects of the Sleeveballoon device are similar to those of the but have distinct advantages over the traditional method. In both, insulin sensitivity and heart functions improved. However, while gastric bypass causes a rapid rise in post food which can cause hypoglycaemia, the Sleeveballoon induces a slowing down of digestion which has a steadying effect on blood sugar levels. This helps control appetite and hunger, keeping the person fuller for longer and substantially reduces weight."

The device should be removed after 6 to 12 months, and the team are eager to test the device in say more research is needed to manage this process and avoid reversal of the positive effects on obesity and diabetes.

"About two billion adults, or 30% of the world's population, live with overweight or obesity according to the World Health Organisation," said Professor Mingrone.

"At present, 500 million people suffer from type 2 diabetes and about two billion people have fatty liver disease. We hope that our discovery will be tested in humans soon and revolutionise the way we tackle this epidemic."


Explore further

Biliopancreatic diversion improves insulin sensitivity, but some concerns remain

More information: James Casella-Mariolo et al. Simulation of gastric bypass effects on glucose metabolism and non-alcoholic fatty liver disease with the Sleeveballoon device, EBioMedicine (2019). DOI: 10.1016/j.ebiom.2019.07.069
Journal information: EBioMedicine

Citation: Type 2 diabetes and obesity could be treated by new, less invasive procedure (2019, October 11) retrieved 14 October 2019 from https://medicalxpress.com/news/2019-10-diabetes-obesity-invasive-procedure.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more